echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > Courtesy View Good Targeted Protein Degradation Platform Receives Another US$70 Million In Help

    Courtesy View Good Targeted Protein Degradation Platform Receives Another US$70 Million In Help

    • Last Update: 2021-09-20
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    On September 9, 2021, Lycia Therapeutics announced the completion of a US$70 million Series B financing


    Targeted protein degradation is one of the hot spots in the field of drug research and development.


    Lycia’s co-founder, "MacArthur Genius Award" winner, and Stanford University chemical biologist Dr.


    Dr.


    Reference materials:

    [1] Lycia Therapeutics Announces $70 Million Series B Financing Led by Redmile Group with Participation from Founding Investor Versant Ventures.


    (The original text has been deleted)

    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.